CTAD (Clinical Trials on Alzheimer's Disease) is the premier international conference focused specifically on clinical trials for [Alzheimer's disease](/diseases/alzheimers-disease) and related dementias. Founded in 2008, CTAD has become the most important venue for presenting late-breaking clinical trial results, discussing novel trial designs, and shaping the future of Alzheimer's therapeutics development[@ctad].
Unlike general neurology meetings that cover a broad range of topics, CTAD exclusively addresses the design, execution, and analysis of clinical trials in the Alzheimer's field. This focused approach makes CTAD the most targeted venue for AD clinical research, attracting key stakeholders including academic researchers, pharmaceutical companies, regulatory agencies (FDA, EMA), and patient advocacy organizations[@cummings2024].
Conference Focus Areas
Clinical Trial Design
CTAD features extensive coverage of innovative clinical trial methodologies:
CTAD (Clinical Trials on Alzheimer's Disease) is the premier international conference focused specifically on clinical trials for [Alzheimer's disease](/diseases/alzheimers-disease) and related dementias. Founded in 2008, CTAD has become the most important venue for presenting late-breaking clinical trial results, discussing novel trial designs, and shaping the future of Alzheimer's therapeutics development[@ctad].
Unlike general neurology meetings that cover a broad range of topics, CTAD exclusively addresses the design, execution, and analysis of clinical trials in the Alzheimer's field. This focused approach makes CTAD the most targeted venue for AD clinical research, attracting key stakeholders including academic researchers, pharmaceutical companies, regulatory agencies (FDA, EMA), and patient advocacy organizations[@cummings2024].
Conference Focus Areas
Clinical Trial Design
CTAD features extensive coverage of innovative clinical trial methodologies:
Platform Trials: Umbrella and platform trial designs enabling multiple treatments to be tested simultaneously under a single protocol
Adaptive Designs: Group sequential designs, sample size re-estimation, and adaptive randomization approaches that allow for modifications during trials
Enrichment Strategies: Biomarker-enriched populations and genetic stratification approaches to identify patients most likely to respond
Endpoint Optimization: Clinical outcome assessment validation and digital endpoint development for more sensitive detection
Statistical Methods: Novel approaches to analyzing cognitive and functional outcomes in diverse populations
Therapeutic Approaches
The conference covers the full spectrum of therapeutic modalities:
Symptomatic Treatments: Cognitive enhancers, behavioral interventions, and novel symptomatic approaches
Prevention Trials: Trials in pre-symptomatic and prodromal populations to delay or prevent disease onset
Combination Therapies: Multi-target approaches for synergistic effects on disease progression
Repurposed Drugs: Existing medications being evaluated for Alzheimer's including diabetes drugs, statins, and anti-inflammatories
Biomarkers
Biomarker development and validation is a major focus:
Fluid Biomarkers: Blood-based tests for amyloid, tau, and neurodegeneration including [p-tau217](/biomarkers/p-tau-217), p-tau181, and [GFAP](/entities/gfap)
Imaging Biomarkers: PET, MRI, and novel imaging techniques for detecting pathology in vivo
Digital Biomarkers: Remote monitoring and passive data collection through wearables and smartphones
Composite Biomarker Panels: Multi-marker approaches for patient stratification and treatment selection
Regulatory Science
CTAD provides a unique forum for regulatory dialogue:
FDA Sessions: Regulatory perspectives on trial design and approval pathways
EMA Workshops: European regulatory considerations and harmonization efforts
Global Harmonization: International regulatory alignment efforts across jurisdictions
Accelerated Approval: Pathways for conditional approvals based on biomarker endpoints
Key Themes in Recent Years
2023-2024: The Therapeutic Revolution
The past two years have witnessed unprecedented progress in Alzheimer's therapeutics:
[Lecanemab](/entities/lecanemab) (Leqembi): Full approval following CLARITY-AD trial demonstrating 27% slowing of cognitive decline[@van2023]
[Donanemab](/entities/donanemab): TRAILBLAZER-ALZ 2 results showing disease modification in early AD[@sims2023]
Anti-tau Therapies: Multiple tau-targeting agents advancing in clinical trials
Blood Biomarkers: Emergence of p-tau217 as a practical diagnostic tool[@palmqvist2023]
2025-2026: Next Generation Therapies
The focus is shifting toward:
Combination Therapies: Testing multiple mechanisms simultaneously to achieve greater efficacy
Earlier Intervention: Trials in pre-symptomatic populations to prevent neurodegeneration
Personalized Medicine: Genetic and biomarker-guided treatment selection